20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

The Role of Olaparib (CAS 763113-22-0) in Advancing Cancer Research and Treatment

The fight against cancer is constantly being advanced by innovative therapeutic agents, and Olaparib (CAS 763113-22-0) plays a pivotal role as a PARP inhibitor. For professionals in the pharmaceutical and biotech industries, understanding the significance and sourcing of such compounds is essential.

Olaparib's primary function is to inhibit Poly(ADP-ribose) polymerase (PARP) enzymes. PARP is crucial for repairing single-strand DNA breaks, a process vital for cell survival. However, cancer cells with specific genetic vulnerabilities, such as BRCA1 or BRCA2 mutations, become highly dependent on PARP for DNA repair. When Olaparib blocks this pathway, it creates lethal accumulation of DNA damage, leading to the death of cancer cells. This targeted mechanism is particularly effective in treating ovarian, breast, pancreatic, and prostate cancers, especially when these genetic mutations are present.

As a manufacturer and supplier, we provide Olaparib of high purity (typically >99%), ensuring its suitability for rigorous scientific research and pharmaceutical development. Researchers utilize Olaparib to explore its efficacy in various cancer models, study resistance mechanisms, and investigate its potential synergies with other treatments. The demand for reliable Olaparib suppliers is high, as consistent quality is paramount for reproducible results.

We, as a manufacturer in China, are committed to delivering not only high-quality Olaparib but also ensuring competitive pricing and a stable supply chain. Whether your needs are for small-scale laboratory research or large-scale pharmaceutical production, we are equipped to meet your requirements. The ability to buy Olaparib from a trusted source simplifies the procurement process for complex research compounds.

The continuous research into Olaparib highlights its potential to improve patient outcomes in numerous cancer types. By providing this essential pharmaceutical intermediate, we aim to support breakthroughs in oncology. We encourage researchers and pharmaceutical companies to partner with us for their Olaparib needs, leveraging our expertise in chemical synthesis and supply chain management.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Olaparib (CAS 763113-22-0): A Key Pharmaceutical Intermediate for Targeted Cancer Therapies

Next: Sourcing Olaparib (CAS 763113-22-0): A Strategic Choice for Pharmaceutical Manufacturers

All Rights Reserved